NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

Today’s positive decision follows the manufacturer, Daiichi Sankyo, offering a fair price for the treatment that the National Institute for Health and Care Excellence (NICE) determined to be ...

Well, we tend to launch in Europe first. And I think this is what you're seeing ... KEYTRUDA with one of the ADCs that we partnered with, whether it's Kulun or Daiichi Sankyo. And we're very excited ...

AstraZeneca and Daiichi Sankyo have moved swiftly to file for ... It is also under review in Europe for both indications. The new BLA is based on the results of the TROPION-Breast01 trial, which ...

Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumors known to express Claudin-6 (CLDN6).

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...

Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

Combining radium-223 with enzalutamide offered a survival benefit in metastatic castration-resistant prostate cancer, but experts questioned its relevance in a shifting treatment landscape.